G Molineux
Overview
Explore the profile of G Molineux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molineux G
Curr Pharm Des
. 2004 Apr;
10(11):1235-44.
PMID: 15078138
Recombinant protein technology produces drugs for human therapy in unprecedented quantity and quality. Research is now focusing on the relationship between pharmacokinetic and pharmacodynamic properties of molecules, with the aim...
2.
Molineux G
Cancer Treat Rev
. 2002 Aug;
28 Suppl A:13-6.
PMID: 12173407
Conjugating biomolecules with polyethylene glycol (PEG), a process known as pegylation, is now an established method for increasing the circulating half-life of protein and liposomal pharmaceuticals. Polyethylene glycols are nontoxic...
3.
Coccia M, Cooke K, Stoney G, Pistillo J, Del Castillo J, Duryea D, et al.
Exp Hematol
. 2001 Oct;
29(10):1201-9.
PMID: 11602322
Objective: We developed a rodent model of noninfectious systemic inflammation to examine the pathogenesis of the associated anemia of chronic disorders (ACD), to evaluate the similarity of this ACD model...
4.
Morstyn G, Foote M, Walker T, Molineux G
Acta Haematol
. 2001 Jul;
105(3):151-5.
PMID: 11463988
SD/01, a sustained-duration molecule, has been developed by adding a poly [ethylene glycol] molecule to the filgrastim molecule. The pegylation does not change the properties of filgrastim, except that the...
5.
LORD B, Woolford L, Molineux G
Clin Cancer Res
. 2001 Jul;
7(7):2085-90.
PMID: 11448927
Filgrastim G-CSF has a short, biologically active half-life, and its effective use depends on repeated inoculations. A major aim, therefore, has been to develop a once-per-chemotherapy cycle formulation. To this...
6.
Coccia M, Hartley C, Sutherland W, Del Castillo J, McElroy P, Pistillo J, et al.
Exp Hematol
. 2001 Feb;
29(1):59-67.
PMID: 11164106
Therapeutic use of recombinant human cytokines in humans can result in the generation of drug-specific antibodies. To predetermine the maximum potential effects of a granulocyte colony-stimulating factor (G-CSF) neutralizing auto-immunoglobulin...
7.
de Haan G, Ausema A, Wilkens M, Molineux G, Dontje B
Br J Haematol
. 2000 Sep;
110(3):638-46.
PMID: 10997976
We have compared the efficacy of a single injection of SD/01, a newly engineered, pegylated form of recombinant human granulocyte colony stimulating factor (rhG-CSF), with a single injection of glycosylated...
8.
Ulich T, Del Castillo J, Senaldi G, Hartley C, Molineux G
Exp Hematol
. 2000 Jan;
27(12):1776-81.
PMID: 10641595
PEG-rHuMGDF administered to normal mice is a lineage-specific growth factor for megakaryocytes and platelets as judged by morphologic examination of hematologic cells in marrow and peripheral blood smears. The purpose...
9.
Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, et al.
Exp Hematol
. 2000 Jan;
27(12):1724-34.
PMID: 10641590
Granulocyte colony-stimulating factor (G-CSF) has proven effective in the prophylaxis of chemotherapy-induced neutropenia and as a mobilizer of peripheral blood progenitor cells. The longevity of G-CSF action is limited by...
10.
Ulich T, Del Castillo J, Senaldi G, Cheung E, Roskos L, Young J, et al.
Exp Hematol
. 1999 Jan;
27(1):117-30.
PMID: 9923450
A single injection of > or =10 microg/kg PEG-rHuMGDF in mice causes a dose-dependent increase in circulating platelets beginning on day 3 and peaking on days 5-6. The mean platelet...